<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01776905</url>
  </required_header>
  <id_info>
    <org_study_id>133965</org_study_id>
    <nct_id>NCT01776905</nct_id>
  </id_info>
  <brief_title>In Vivo Real-time Detection of Circulating Melanoma Cells</brief_title>
  <official_title>In Vivo Real-time Detection of Circulating Melanoma Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arkansas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical trial is to determine whether a Photoacoustic flow cytometry&#xD;
      (PAFC)-based prototype device can detect circulating tumor cells (CTCs) in the blood of&#xD;
      melanoma patients in vivo, in real time, and do so at detection limits at least one order of&#xD;
      magnitude below the detection limits of currently existing ex vivo methods.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Population: Approximately 80 subjects will be consented in order to achieve an&#xD;
      enrollment goal of 75 subjects at this institution in three cohorts as follows:&#xD;
&#xD;
        1. Cohort #1 will consist of fifteen healthy control subjects, ten of whom will be&#xD;
           Caucasian and five of whom will be African-American. Subjects in cohort #1 will be used&#xD;
           to address the calibration goal of Specific Aim #1.&#xD;
&#xD;
        2. Cohort #2 will consist of 30 subjects who have advanced-stage melanoma will be recruited&#xD;
           from the Medical Oncology clinic at UAMS, where advanced stages are defined as Stages&#xD;
           III or IV. Subjects in cohort #2 will be used to address the validation goal of Specific&#xD;
           Aim #2. Approximately half of the 30 advanced-stage subjects will be Stage III and the&#xD;
           other half will be Stage IV.&#xD;
&#xD;
        3. Cohort #3 will consist of 30 subjects with early-stage melanoma will be recruited from&#xD;
           the Surgical Oncology clinic at UAMS, where early stages are defined as Stages I or II.&#xD;
&#xD;
      Subjects in cohort #3 will be used to address the detection goal of Specific Aim #3.&#xD;
      Approximately 10 of the 30 early-stage subjects will be Stage I and approximately 20 will be&#xD;
      Stage II.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2013</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants that possess circulating tumor cells.</measure>
    <time_frame>14-21 days</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Healthy control subjects</arm_group_label>
    <description>Characterize the baseline PA signals produced by the in vivo PAFC prototype device in healthy volunteers or Develop Standard Curves for the ex vivo CTC assays.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Advanced-Stage Melanoma</arm_group_label>
    <description>To validate the in vivo PAFC method of melanoma CTC detection, we will use the PAFC-based prototype device to noninvasively determine CTC concentrations in the blood of subjects who have advanced-stage (Stage III or Stage IV)melanoma, and we will also use current ex vivo methods to determine the CTC concentration in samples of blood drawn from the same subjects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Early-Stage Melanoma</arm_group_label>
    <description>To determine whether in vivo PAFC can detect melanoma CTCs at concentrations below the detection limits of the ex vivo methods, we will use the PAFC-based prototype device to noninvasively detect CTCs in the blood of subjects who have early-stage (Stages I or II) melanoma, and we will also use current ex vivo methods to detect CTCs in samples of blood drawn from the same subjects.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Expect to consent approximately 80 subjects in order to achieve an enrollment goal of 75&#xD;
        subjects at this institution in three cohorts.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 to 80 years&#xD;
&#xD;
          -  Histological documented diagnosis of melanoma&#xD;
&#xD;
          -  Signed informed consent form approved by the University of Arkansas for Medical&#xD;
             Sciences (UAMS) Institutional Review Board (IRB)&#xD;
&#xD;
          -  Must be able to sit still for 90 minutes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active infection&#xD;
&#xD;
          -  Current and significant medical or surgical condition as determined by the&#xD;
             Investigator&#xD;
&#xD;
          -  Diagnosis or evidence of organic brain syndrome&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Issam Makhoul, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arkansas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Issam Makhoul, MD</last_name>
    <phone>501-526-6990</phone>
    <email>MakhoulIssam@uams.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brittany Lehman</last_name>
    <phone>5016868274</phone>
    <email>blehman@uams.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vladimir Zharov, PhD</last_name>
      <phone>501-603-1213</phone>
      <email>ZharovVladimirP@uams.edu</email>
    </contact>
    <investigator>
      <last_name>Fade Mahmoud</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vladimir Zharov, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ekaterina Galanzha, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sara Shalin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 14, 2013</study_first_submitted>
  <study_first_submitted_qc>January 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2013</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Melanoma</keyword>
  <keyword>Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

